We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Medicinal Plants of the Peruvian Amazon: Bioactive Phytochemicals, Mechanisms of Action, and Biosynthetic Pathways

Juan Carlos Castro, Joseph Dylan Maddox, Marianela Cobos, Jae Diana Paredes, Anthony Jhoao Fasabi, Gabriel Vargas-Arana, Jorge Luis Marapara, Pedro Marcelino Adrianzen, María Zadith Casuso and Segundo Levi Estela

Abstract

The objective of this book chapter is to provide consolidated and updated scientific information about the medicinal plants of the Peruvian Amazon, which has a great richness of plants; many of these are used in folkloric medicine to treat several diseases. Recently, investigations have reported that these medicinal plants possess bioactive phytochemicals against several diseases such as diabetes, cancer, inflammation, infectious diseases, and several other health problems, thus corroborating some ethnopharmacological reports. The mechanism of action for selected bioactive phytochemicals was demonstrated at the molecular level as well as the metabolic pathways involved in their biosynthesis were described. Due to the large gap in scientific information revealed in this review, we formulated a series of strategies to close these scientific knowledge gaps and achieve a sustainable exploitation of medicinal plants in the Peruvian Amazon.

Keywords: cancer, diabetes, ethnopharmacological survey, folkloric medicine

1. Introduction

Peru is cataloged as a megadiverse country due to its great diversity of species, particularly in plants [1, 2]. This diversity is attributed to the large number of eco-regions present in our territory [3], which were originated by their particular geologic evolution [4]. The Peruvian Amazon includes a large proportion of this richness in plant species, and several are endemic to this region [5, 6]. The diversity, however, remains underestimated because until now a complete and updated inventory of plant species is lacking, but some estimates suggest that more than 50% of plant species are unknown to science [7, 8].

Similarly, there are many gaps in the scientific knowledge of medicinal plants of the Peruvian Amazon. These gaps are evident at various knowledge levels from the inventory of medicinal plants and their taxonomic identification, the bioactive phytochemicals produced, the mechanisms of action of the bioactive phytochemicals, and the metabolic pathways involved in the biosynthesis of bioactive phytochemicals. In part, these gaps in the scientific knowledge can be attributed to several factors: (1) the ethnopharmaceutical information has been obtained from few ethnic groups (probably <10%); (2) the majority of ethnopharmaceutical surveys have been focused on plant species to treat protozoal diseases, with particular emphasis on malaria and leishmania [9–12]; and (3) the research centers in the Peruvian Amazon generally lack trained scientist, laboratory equipment, and standard methods to perform bioassays for the discovery of bioactive phytochemicals against diabetes, inflammation, hypertension, cancer, infectious diseases (viral, bacterial, and fungal), and other health problems. Consequently, it is fundamental to implement strategies to surpass these limitations and to close these large knowledge gaps.

Parts of the problems mentioned are addressed in this book chapter that consists of six topics. The first topic “The diversity of plants in the Peruvian Amazon” describes the diversity of species reported for the country and the Peruvian Amazon and are mentioned the possible factors involved in light of current knowledge. The second topic “Medicinal plants and indigenous people in the Peruvian Amazon” highlights information about medicinal plants and ethnic groups. Relevant information of the recently elaborated partial database of medicinal plants is also discussed. The third topic “Some bioactive phytochemicals identified in medicinal plants” presents structures of bioactive phytochemicals against cancer, inflammation, diarrhea, malaria, and diabetes. The fourth topic “Mechanism of action of select bioactive phytochemicals” explains the molecular bases of the mechanisms of action of well-characterized phytochemicals such as taspine, crofelemer, mitraphylline, quercetin, linalool, and bixin. The fifth topic “Biosynthetic pathways for relevant bioactive phytochemicals” describes and provides graphically key metabolic pathways involved in the biosynthesis of quercetin, linalool, and bixin. The final topic “Strategies for the sustainable use of medicinal plants” recommends the adoption of strategies to accelerate the generation of scientific knowledge that permits a sustainable exploitation of the medicinal plants in the Peruvian Amazon.

2. The diversity of plants in the Peruvian Amazon

The plant diversity in the Amazonian lowland rain forest is astounding. This diversity was recently demonstrated with a large-scale taxonomic inventory, which identified 14,003 species; 1788 genera; and 188 families of seed plants, in which 50% of these species can reach ≥ 10 cm stem diameter at breast height (DBH). More than 52% of seed plant species diversity in this region include shrubs, small trees, lianas, vines, and herbs [1]. The Peruvian Amazon includes ~39% (5401 species) of these species. Also, a previous study showed that a forest near to Iquitos is the most species-rich in the world, with ~300 species ≥ 10 cm in DBH [2]. In addition, it is estimated that ~17,143 plant species are circumscribed within the national boundaries [13], and approximately 13% of these plant species are endemic to the Peruvian Amazon [5, 6]. It is speculated, however, that only 60% of the Peruvian flora has been identified [7]. Consequently, Peru is considered to be one of the 17 megadiverse countries, a global center for species

richness of plants and other organisms [14]. This peculiarity is attributed to the most Holdridge life zones (containing 84 of the 107 eco-regions of the world) that possess our country [3], which was determined for their particular geologic evolution [4].

3. Medicinal plants and indigenous people in the Peruvian Amazon

The Amazon lowland rain forest provides multiple benefits to its inhabitants [15]. According to Schultes [16], rain forests have an incalculable value as an untapped emporium of germplasm for new commercial plants. For example, to the inhabitants of Mishana (a community near Iquitos), the tropical forest provides timber resources (e.g., sawlogs and pulpwood) and several forest products such as edible fruits, oils, latex, fiber, and medicines. The yield of these forest products is provided by 72 species (26.2%) that are sold in the Iquitos market [17]. In addition, it is estimated that ~4400 native plant species of the Peruvian flora are used by inhabitants for 49 different applications [18]. With reference to bioactive plants, it was reported that more than 1300 species are used by natives in the northwest Amazon as medicines, poisons, or narcotics [16]. To date, however, the list of medicinal plants useful for the discovery and development

Figure 1.
Families of medicinal plants (A) and number of their uses (B) to treat diseases in the Peruvian Amazon.

Figure 2.
Selected ethnic groups from the Peruvian Amazon.

of drugs is fragmentary and incomplete, because the ethnopharmacological surveys conducted in the Peruvian Amazon are sporadic and scarce. Recently, we elaborated a partial database of medicinal plants of the Peruvian Amazon, which is based on the few available ethnobotanical studies [9–12, 19–25], one list of the Research Institute of The Peruvian Amazon (IIAP) and surveys carried out by our research group in the *Pasaje Paquito* (the main center for commercialization of medicinal plants in the Loreto region, Iquitos). The medicinal plant database includes 1410 species belonging to 157 plant families; these taxonomic assignments were verified with the Plant List database (<http://www.theplantlist.org/>). Of these, the top 10 families by number of medicinal plant species are Fabaceae (137), Asteraceae (80), Rubiaceae (57), Araceae (53), Piperaceae (51), Solanaceae (51), Euphorbiaceae (47), Apocynaceae (39), Bignoniaceae (39), and Clusiaceae (32). In addition, this database reveals that the plant families with the highest number of medicinal uses are Fabaceae (272), Asteraceae (244), Rubiaceae (197), Euphorbiaceae (180), Piperaceae (179), and Solanaceae with 166 medicinal uses (**Figure 1**).

It is paradoxical that only some ethnic groups were evaluated to date for ethnopharmacological surveys, given the Peruvian Amazon's ethnic diversity (**Figure 2**). According to a recent national census, the indigenous population of the Peruvian Amazon consists of 332,975 inhabitants that include 13 linguistic families that are grouped into 51 ethnic groups. Of the total number of communities registered, 21 are polyethnic [26, 27]. In all these ethnic groups, the millenary knowledge of medicinal plants used to combat common diseases is a fundamental component within the indigenous health systems, which has been maintained from generation to generation. However, due to the transculturation by modernization and globalization, this ancestral knowledge is being lost [15]. Consequently, it is necessary to implement strategies to preserve this invaluable knowledge for the benefit of humankind.

4. Some bioactive phytochemicals identified in medicinal plants

Presently, the list of medicinal plants of the Peruvian Amazon is partial; in consequence, only for the most known plants were identified a few bioactive phytochemicals (**Figure 3**). There is no way to estimate how many new biochemical structures, probably of great value to humankind, remain undiscovered in the Peruvian Amazon. Some of the phytochemicals isolated and with corroborated bioactivity against cancer [28], inflammation [29], diarrhea [30], malaria [31], diabetes [32], and several other diseases were determined [33].

Figure 3.
A small selection of bioactive phytochemicals identified in medicinal plants of the Peruvian Amazon.

5. Mechanism of action of select bioactive phytochemicals

5.1 Bixin

Bixin constitutes the main pigment of the industrial annatto obtained from the seed coat of *Bixa orellana* [34]. This phytochemical belongs to the relatively small family of apocarotenoids; it was the first cis-carotenoid to be isolated from natural sources [35]. However, it was not until 1961 that its chemical structure and stereochemistry were determined through nuclear magnetic resonance spectroscopy studies [36].

This phytochemical compound shows pleiotropic bioactivities with health-promoting properties. It was recently demonstrated that bixin caused arrest of Hep3B cell line at G2/M checkpoint of the cell cycle and the molecular mechanism of action was demonstrated by a modeling study, which was based in the favorable

binding of bixin to domains of Bax BH3 and FasL proteins [37]. Consequently, bixin should be used for developing agents to combat human hepatocellular carcinoma. Bixin is also a potent activator of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), which is the master regulator of the cellular antioxidant response protecting the skin against various environmental stressors including UV radiation and electrophilic pollutants [38–40]. The protective effects against solar UV-induced skin damage are due to the NRF2-dependence of bixin-induced antioxidant and anti-inflammatory effects [39]. In addition, bixin displays molecular activities as antioxidant, excited-state quencher, peroxisome proliferator-activated receptor α/γ agonist, and Toll-like receptor 4/nuclear factor kappa-light-chain-enhancer of activated B-cell antagonist. Together, these bioactivities may be important to the improvement of skin barrier function and environmental stress protection [40].

5.2 Crofelemer

Crofelemer previously known as SP-303 is a large proanthocyanidin oligomer isolated from the bark latex of the plant *Croton lechleri* Müll. Arg. [41]. Initial studies have demonstrated the immense antiviral activity of crofelemer against a gamma of DNA and RNA viruses such as respiratory syncytial virus, influenza A virus, parainfluenza virus, herpesvirus types 1 and 2, and hepatitis A and B viruses. The antiviral mechanism implies the direct interaction of crofelemer to components of the viral envelope, blocking both the viral attachment and the cell invasion [41]. More recently, crofelemer is used as a first-in-class antidiarrheal medication, and its efficacy has been investigated *in vivo* assays [42] and in patients with HIV-associated diarrhea, diarrhea of various infectious etiologies, as well as diarrhea-predominant irritable bowel syndrome [43]. Crofelemer was recently approved by the FDA to treat diarrhea in HIV/AIDS patients on antiretroviral therapy [44].

The mechanism of action as antidiarrheal of this proanthocyanidin oligomer consists in the dual inhibitory action on two structurally unrelated prosecretory intestinal Cl[−] channels, which are responsible for chloride secretion and subsequent luminal hydration. The first target is an extracellular site of the cystic fibrosis transmembrane regulator (CFTR) Cl[−] channel ($\sim 60\%$, IC₅₀ ~ 7 μM), which produces a voltage-independent block with stabilization of the channel closed state. The second target is the intestinal calcium-activated Cl[−] channel (CaCC) by a voltage-independent inhibition mechanism ($>90\%$, IC₅₀ ~ 6.5 μM) [45].

5.3 Linalool

An abundant ($\sim 90\%$) essential oil of the leaves of *Aniba rosaeodora* [46, 47] that is used in the traditional medicine of the Peruvian and Brazilian Amazon for its effects on the central nervous system, such as sedative, anticonvulsant, and antidepressant [19, 47, 48]. Additionally, linalool has anti-inflammatory [49], anticancer [50–52], antihyperlipidemic, antinociceptive, analgesic, anxiolytic, and neuroprotective properties [53]. Several studies have demonstrated a gamma of anti-infectious activity like antiviral [54], antibacterial [55–57], antifungal [58, 59], and antileishmanial [55, 60, 61].

The anticancer mechanisms of action of linalool in hepatocellular carcinoma (HCC) HepG2 cells were recently revealed by Rodenak-Kladniew et al. [50] (**Figure 4**). According to these researchers, linalool in a dose-dependently blocked cell proliferation by inducing G0/G1 cell cycle arrest, through Cdk4 and cyclin A downregulation, p21 and p27 upregulation, and apoptosis, characterized by

Figure 4.
Anticancer mechanisms of action of linalool in hepatocellular carcinoma (HCC) HepG2 cells.

mitochondrial membrane potential loss, caspase-3 activation, poly(ADP-ribose) polymerase cleavage, and DNA fragmentation

5.4 Mitraphylline

A pentacyclic oxindolic alkaloid that was isolated from the alkaloid fraction of the dried inner bark of *Uncaria tomentosa* (Willd. ex Schult.) DC; it represents the most abundant phytochemical (40%) of the alkaloid fraction [62]. Several investigations have demonstrated the immunoregulatory activity of this compound or the pentacyclic oxindolic alkaloid-enriched fraction [63–67].

The mechanism of action as immunoregulator of mitraphylline consists in both to protect cells against oxidative stress and to elicit a response via an NF- κ B-dependent mechanism. The first mechanism is based on the inhibition of the inducible nitric oxide synthase gene expression; consequently, nitrite formation and programmed cell death are avoided. Finally, in the second mechanism, the inhibition of NF- κ B signaling permits the abrogation of the release of pro-inflammatory cytokines such as TNF α , IL-6, IL-1 α , IL-1 β , IL-4, IL-17, and IFN- α [63–67].

5.5 Quercetin

A polyphenol categorized as a flavonol, one of the five subclasses of flavonoid compounds. This bioactive phytochemical is biosynthesized and accumulated in

tissues and organs of several medicinal plants of the Peruvian Amazon such as *Annona montana*, *Bauhinia longifolia*, *Bertholletia excelsa*, *Genipa americana*, *Inga edulis*, *Mauritia flexuosa*, *Myrciaria dubia*, *Oenocarpus bataua*, *Solanum sessiliflorum*, *Theobroma bicolor*, *T. cacao*, and *T. grandiflorum* [68–70]. Quercetin exhibits multifaceted therapeutic applications for multiplicity of unrelated acute and chronic human ailments like allergy, arthritis, asthma, bacterial and viral infections, cancer, cardiovascular diseases, inflammation, obesity, diabetes, mood disorders, neuropathologies, and other health problems [71–76].

This multiple health beneficial properties of quercetin are attributed to their particular mechanism of action based on inhibition of several key proteins and enzymes (**Figure 5**). For example, a recent research showed that this compound is a potent inhibitor of 25 human serine/threonine kinases [77]. The multitarget inhibitor explains its beneficial pleiotropic effects on humans. This flavonoid-type inhibitor is effective against xanthine oxidase, appropriate for the treatment of hyperuricemia, gout, and inflammatory disease states. The inhibitory mechanism is based on the favorable steric complementarity of the conjugated three-ring structure of quercetin with the active site of xanthine oxidase. The enzyme-quercetin binary complex is stabilized by van der Waals forces and hydrogen-bonding interactions with both binding and catalytic amino acid residues, respectively [78, 79]. Recently, Hamilton et al. [80] have demonstrated that quercetin is a competitive inhibitor of glucose uptake by GLUT1. These researchers showed that the inhibitory effect is simply by binding of quercetin to the surface of GLUT1 [80]. Finally, several structural studies by X-ray diffraction have corroborated the inhibitory complex of quercetin with several human protein kinases [81–83].

5.6 Taspine

An alkaloid isolated for the first time by Vaisberg et al. [84] from the bark latex of the plant species *Croton lechleri* Müll. Arg. Previous *in vitro* and *in vivo* investigations have demonstrated that taspine promotes early phases of wound healing in a dose-dependent manner [84, 85]. Taspine was also demonstrated to activate the pro-apoptotic cascade, which oligomerizes Bak/Bax into pores that result in the release of cytochrome c and consequently apoptosis in HCT116 colon carcinoma cells [86]. Similar results were reported for an *in vivo* study conducted with ZR-75-30 human breast cancer xenografts in athymic mice [87].

The mechanism of action of taspine as a topoisomerase inhibitor was revealed recently. Initially, using *in vitro* assays, Fayad et al. [86] observed the inhibition of both topoisomerases I and II by taspine. Castelli et al. [88] corroborated the

Figure 5.
Inhibitory complex of quercetin with selected human kinase targets.

inhibitory action of taspine on purified topoisomerase I and provided the molecular details of the inhibitory action. These researchers showed that taspine inhibits the catalytic process (cleavage and religation), and molecular docking simulations showed that the formation of the complex enzyme-taspine is accomplished by the interaction in the proximity of the active site preventing the cleavage reaction. While, that the religation inhibition is explained by DNA intercalation of the inhibitor with the enzyme-DNA-binary complex.

6. Biosynthetic pathways for relevant bioactive phytochemicals

6.1 Bixin biosynthesis

The biosynthesis of the apocarotenoid ester bixin from lycopene requires four enzymatic reactions (**Figure 6**). The first enzymatic reaction of bixin biosynthesis is the 5-6/5'-6' oxidative cleavage of lycopene catalyzed by lycopene cleavage oxygenase to produce two sulcatone and one bixin aldehyde molecule. The second enzymatic reaction is the oxidative conversion of aldehyde into carboxylic acid groups in bixin aldehyde to produce norbixin by bixin aldehyde dehydrogenase. The third enzymatic reaction is the methylation of one norbixin carboxyl group to produce bixin by norbixin methyltransferase. This enzyme utilizes *S*-adenosyl-L-methionine as a methyl-group donor. Finally, the last biochemical reaction is the methylation of one bixin carboxyl group to produce bixin dimethyl ester by bixin methyltransferase, using *S*-adenosyl-L-methionine as methyl-group donor [89–91].

6.2 Linalool biosynthesis

The fundamental building blocks in plants for terpenoid production, i.e., isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), are generated via two independent pathways, namely, 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway and the mevalonate acid (MVA) pathway [92, 93]. The plastid terpenes are formed exclusively via the MEP pathway; however, sterols are biosynthesized via MVA pathway in the cytoplasm and mitochondria [94, 95]. Radiolabeling studies in the early 1970s showed that in *Cinnamomum camphora* the biosynthesis of linalool is accomplished via the MVA pathway [96]. Nevertheless, recent transcriptome analysis of leaves in two chemotypes of *C. camphora* showed that both pathways provide the biosynthetic precursors IPP and DMAPP for the main monoterpenes (i.e., linalool and borneol) synthesis [97]. The balance of IPP/DMAPP is controlled by type 1 and type 2 isopentenyl diphosphate:dimethylallyl diphosphate isomerase, which reversibly converts IPP to DMAPP [98, 99]. Further, IPP and DMAPP are condensed by geranyl diphosphate synthase and isopentenyl diphosphate to produce geranyl diphosphate by geranyl diphosphate synthase. Finally, geranyl diphosphate is transformed in linalool by the action of linalool synthase (**Figure 7**).

6.3 Quercetin biosynthesis

A bioactive phytochemical that is biosynthesized through the phenylpropanoid pathway [100]. The initial reactions transform phenylalanine into 4-coumaroyl-CoA, which enters into the flavonoid biosynthesis pathway (**Figure 8**). The first committed enzyme in the flavonoid pathway, chalcone synthase, uses malonyl-CoA and 4-coumaroyl-CoA as substrates to produce naringenin chalcone. This metabolic

superpathway of carotenoid biosynthesis in plants

Figure 6.
Biosynthetic pathway for bixin.

intermediary is converted to (+)-dihydrokaempferol by the action of two enzymes, one isomerase and one dioxygenase, respectively. Next, (+)-dihydrokaempferol quercetin is biosynthesized by two alternative and consecutive enzymatic reactions: first, enzymes (+)-dihydrokaempferol 3'-hydroxylase and quercetin synthase produce (+)-taxifolin as a metabolic intermediary, and, second, enzymes dihydrokaempferol synthase and kaempferol monooxygenase produce kaempferol as a metabolic intermediary [101].

Figure 7.
 Biosynthetic pathway for linalool through the MEP pathway.

7. Strategies for the sustainable use of medicinal plants

To date, the research contributions of the Peruvian Amazon to ethnopharmacology have been very limited, and data are still fragmentary and dispersed. Consequently, to ensure a sustainable economic development, we need to obtain a competitive advantage based on our medicinal plant resources. To achieve these goals, we must formulate appropriate strategies based on solid scientific knowledge. First, we need to record the millenary knowledge of folk medicine practiced by the total ethnic groups of the Peruvian Amazon. Second, based on this information, we

Figure 8.
Biosynthetic pathway for quercetin.

should construct a complete catalog of known medicinal plants with correct taxonomic identifications. Third, an enriched germplasm bank of medicinal plants should be established with accessions of several sites of the Peruvian Amazon. Fourth, the bioactivity of extracts/bio-guided isolated and purified phytochemicals with a battery of *in vitro* and *in vivo* standardized bioassays against multiple diseases (e.g., diabetes, cancer, bacterial infections, etc.) should be established. Fifth, multiomics approaches such as genomics, transcriptomics, proteomics, and metabolomics should be performed to identify key genes, enzymes, and metabolic pathways responsible for the biosynthesis of promising bioactive phytochemicals. Sixth, in the short term, a web-based computerized database to facilitate storage, management, transfer and

exchange, and analysis of the data by researchers, planners, and other interested users should be developed and made freely available. Finally, the availability of this basic scientific information could support the development of genetic improvement programs for medicinal plants and allow a boost of biotechnological applications, based on synthetic biology tools and using bacterial, microalgal, and several other cell-/tissue-based platforms for the production of phytochemical compounds of interest, thus preventing overexploitation and species extinction of medicinal plants.

8. Conclusions

The Peruvian Amazon houses multiple medicinal plants, but the species catalog is still incomplete, because ethnopharmaceutical studies are lacking in the great majority of ethnic groups. A select number of medicinal plant species, however, have been identified as a potentially useful source of bioactive phytochemical compounds to treat various diseases such as diabetes, cancer, inflammation, and infections caused by pathogens, among other health problems. Also, for some of these bioactive phytochemical compounds, the mechanisms of action are known, which are characterized by presenting a common pattern, their pleiotropic effects, which is attributable to act on multiple targets, consequently, affecting various cellular processes. In relation to the metabolic pathways responsible for biosynthesis of these molecules, only very few are known, but for the vast majority of phytochemicals, it remains a great mystery that needs to be clarified. Therefore, we formulated a series of strategies to close these scientific knowledge gaps and achieve a sustainable exploitation of medicinal plants in the Peruvian Amazon.

Acknowledgements

This research was supported by grants from Universidad Nacional de la Amazonía Peruana (UNAP). We also thank and especially dedicate this chapter book to Janeth Braga Vela, who is a great professor and guide and an exceptional and inspiring woman.

Conflict of interest

The authors declare no conflict of interest.

IntechOpen

Author details

Juan Carlos Castro^{1*}, Joseph Dylan Maddox^{2,3}, Marianela Cobos⁴, Jae Diana Paredes⁴, Anthony Jhoao Fasabi¹, Gabriel Vargas-Arana^{5,6}, Jorge Luis Marapara¹, Pedro Marcelino Adrianzen¹, María Zadith Casuso⁴ and Segundo Levi Estela⁴

1 Specialized Unit of Biotechnology, Research Center of Natural Resources of the Amazon (CIRNA), National University of the Peruvian Amazon (UNAP), Iquitos, Peru

2 Pritzker Laboratory for Molecular Systematics and Evolution, The Field Museum of Natural History, Chicago, IL, USA

3 Environmental Sciences, American Public University System, Charles Town, WV, USA

4 Laboratory of Biotechnology and Bioenergetics, Scientific University of Peru (UCP), Iquitos, Peru

5 Laboratory of Natural Products Chemistry, Research Institute of the Peruvian Amazon (IIAP), Iquitos, Peru

6 Peruvian University of the East (UPO), Iquitos, Peru

*Address all correspondence to: juan.castro@unapiquitos.edu.pe

IntechOpen

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] Cardoso D, Särkinen T, Alexander S, Amorim AM, Bittrich V, Celis M, et al. Amazon plant diversity revealed by a taxonomically verified species list. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;**114**:10695-10700. DOI: 10.1073/pnas.1706756114
- [2] Gentry AH. Tree species richness of upper Amazonian forests. *Proceedings of the National Academy of Sciences of the United States of America*. 1988;**85**:156-159. DOI: 10.1073/pnas.85.1.156
- [3] Holdridge LR. *Life Zone Ecology*. Costa Rica. Tropical Science Center; 1967. 206 p
- [4] Hoorn C, Wesselingh FP, ter Steege H, Bermudez MA, Mora A, Sevink J, et al. Amazonia through time: Andean uplift, climate change, landscape evolution, and biodiversity. *Science*. 2010;**330**:927-931. DOI: 10.1126/science.1194585
- [5] Rodríguez LO, Young KR. Biological diversity of Peru: Determining priority areas for conservation. *Ambio: A Journal of the Human Environment*. 2000;**29**:329-337. DOI: 10.1579/0044-7447-29.6.329
- [6] van der Werff H, Consiglio T. Distribution and conservation significance of endemic species of flowering plants in Peru. *Biodiversity and Conservation*. 2004;**13**:1699-1713. DOI: 10.1023/B:BIOC.0000029334.69717.f0
- [7] Brack A. *Perú: Biodiversidad, pobreza y bionegocios*. Lima, Perú: Programa de las Naciones Unidas para el Desarrollo; 2004
- [8] Joppa LN, Roberts DL, Myers N, Pimm SL. Biodiversity hotspots house most undiscovered plant species. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;**108**:13171-13176. DOI: 10.1073/pnas.1109389108
- [9] Céline V, Adriana P, Eric D, Joaquina A, Yannick E, Augusto LF, et al. Medicinal plants from the Yanesha (Peru): Evaluation of the leishmanicidal and antimalarial activity of selected extracts. *Journal of Ethnopharmacology*. 2009;**123**:413-422. DOI: 10.1016/j.jep.2009.03.041
- [10] Ruiz L, Ruiz L, Maco M, Cobos M, Gutierrez-Choquevilca A-L, Roumy V. Plants used by native Amazonian groups from the Nanay River (Peru) for the treatment of malaria. *Journal of Ethnopharmacology*. 2011;**133**:917-921. DOI: 10.1016/j.jep.2010.10.039
- [11] Vásquez-Ocmín P, Cojean S, Rengifo E, Suyyagh-Albouz S, Amasifuen Guerra CA, Pomel S, et al. Antiprotozoal activity of medicinal plants used by Iquitos-Nauta road communities in Loreto (Peru). *Journal of Ethnopharmacology*. 2018;**210**:372-385. DOI: 10.1016/j.jep.2017.08.039
- [12] Estevez Y, Castillo D, Pisango MT, Arevalo J, Rojas R, Alban J, et al. Evaluation of the leishmanicidal activity of plants used by Peruvian Chayahuita ethnic group. *Journal of Ethnopharmacology*. 2007;**114**:254-259. DOI: 10.1016/j.jep.2007.08.007
- [13] Brako L, Zarucchi JL. *Catalogue of the Flowering Plants and Gymnosperms of Peru*. 6th ed. St. Louis, Mo: Missouri Botanical Garden; 1993. 1286 p
- [14] Mittermeier RA, Mittermeier CG. *Megadiversity: Earth's Biologically Wealthiest Nations*. CEMEX; 1997. 501 p
- [15] Bennett BC. Plants and people of the Amazonian rainforests. *Bioscience*. 1992;**42**:599-607. DOI: 10.2307/1311925

- [16] Schultes RE. The Amazonia as a source of new economic plants. *Economic Botany*. 1979;**33**:259-266. DOI: 10.1007/BF02858251
- [17] Peters CM, Gentry AH, Mendelsohn RO. Valuation of an Amazonian rainforest. *Nature*. 1989;**339**:655-656. DOI: 10.1038/339655a0
- [18] Brack A. Diccionario enciclopédico de plantas útiles del Perú. Lima, Perú: Programa de las Naciones Unidas para el Desarrollo; 1999
- [19] Mejía K, Rengifo E, Vila C. Plantas Medicinales de uso popular en la Amazonía Peruana. Iquitos, Perú: Agencia Española de Cooperación Internacional (AECI), Instituto de Investigaciones de la Amazonía Peruana; 2000
- [20] Sanz-Biset J, Campos-de-la-Cruz J, Epiquién-Rivera MA, Cañigueral S. A first survey on the medicinal plants of the Chazuta valley (Peruvian Amazon). *Journal of Ethnopharmacology*. 2009;**122**:333-362. DOI: 10.1016/j.jep.2008.12.009
- [21] Odonne G, Valadeau C, Alban-Castillo J, Stien D, Sauvain M, Bourdy G. Medical ethnobotany of the Chayahuita of the Paranapura basin (Peruvian Amazon). *Journal of Ethnopharmacology*. 2013;**146**:127-153. DOI: 10.1016/j.jep.2012.12.014
- [22] Odonne G, Bourdy G, Castillo D, Estevez Y, Lancha-Tango A, Alban-Castillo J, et al. Ta'ta' Huayani: Perception of leishmaniasis and evaluation of medicinal plants used by the Chayahuita in Peru. Part II. *Journal of Ethnopharmacology*. 2009;**126**:149-158. DOI: 10.1016/j.jep.2009.07.015
- [23] Valadeau C, Castillo JA, Sauvain M, Lores AF, Bourdy G. The rainbow hurts my skin: Medicinal concepts and plants uses among the Yanesha (Amuesha), an Amazonian Peruvian ethnic group. *Journal of Ethnopharmacology*. 2010;**127**:175-192. DOI: 10.1016/j.jep.2009.09.024
- [24] Sanz-Biset J, Cañigueral S. Plants as medicinal stressors, the case of depurative practices in Chazuta valley (Peruvian Amazonia). *Journal of Ethnopharmacology*. 2013;**145**:67-76. DOI: 10.1016/j.jep.2012.09.053
- [25] Rainer WB, Douglas S. Medicinal Plants of the Andes and the Amazon: The Magic and Medicinal Flora of Northern Peru. Trujillo, Perú: William L. Brown Center; 2015. 292 p
- [26] ¿Qué es la BDPI? Base de Datos de Pueblos Indígenas u Originarios. Available from: <http://bdpi.cultura.gob.pe/> [Accessed: October 23, 2018]
- [27] Perú Instituto Nacional de Estadística e Informática. Available from: <https://www.inei.gob.pe/> [Accessed: October 23, 2018]
- [28] Wang S-C, Lu M-C, Chen H-L, Tseng H-I, Ke Y-Y, Wu Y-C, et al. Cytotoxicity of calotropin is through caspase activation and downregulation of anti-apoptotic proteins in K562 cells. *Cell Biology International*. 2009;**33**:1230-1236. DOI: 10.1016/j.cellbi.2009.08.013
- [29] Junyuan Z, Hui X, Chunlan H, Junjie F, Qixiang M, Yingying L, et al. Quercetin protects against intestinal barrier disruption and inflammation in acute necrotizing pancreatitis through TLR4/MyD88/p38 MAPK and ERS inhibition. *Pancreatology*. 2018;**18**:742-752. DOI: 10.1016/j.pan.2018.08.001
- [30] Van Seville YZA, Gibson RJ, Wardill HR, Ball IA, Keefe DMK, Bowen JM. Dacomitinib-induced diarrhea: Targeting chloride secretion

with crofelemer. International Journal of Cancer. 2018;**142**:369-380. DOI: 10.1002/ijc.31048

[31] Sá MS, de Menezes MN, Krettli AU, Ribeiro IM, Tomassini TCB, Ribeiro dos Santos R, et al. Antimalarial activity of physalins B, D, F, and G. Journal of Natural Products. 2011;**74**:2269-2272. DOI: 10.1021/np200260f

[32] Wang H-Y, Kan W-C, Cheng T-J, Yu S-H, Chang L-H, Chuu J-J. Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese *Momordica charantia* between type 1 and type 2 diabetic mice. Food and Chemical Toxicology. 2014;**69**:347-356. DOI: 10.1016/j.fct.2014.04.008

[33] Kaneshima T, Myoda T, Toeda K, Fujimori T, Nishizawa M. Antimicrobial constituents of peel and seeds of camu-camu (*Myrciaria dubia*). Bioscience, Biotechnology, and Biochemistry. 2017;**81**:1461-1465. DOI: 10.1080/09168451.2017.1320517

[34] Zechmeister L. Cis-trans isomerization and stereochemistry of carotenoids and diphenyl-polyenes. Chemical Reviews. 1944;**34**:267-344. DOI: 10.1021/cr60108a004

[35] Karrer P, Helfenstein A, Widmer R, van Itallie TB. Über Bixin. (XIII. Mitteilung über Pflanzenfarbstoffe.). Helvetica Chimica Acta. 1929;**12**:741-756. DOI: 10.1002/hlca.19290120174

[36] Barber MS, Hardisson A, Jackman LM, Weedon BCL. Studies in nuclear magnetic resonance. Part IV. Stereochemistry of the bixins. Journal of the Chemical Society. 1961;**0**:1625-1630. DOI: 10.1039/JR9610001625

[37] Kumar Y, Phaniendra A, Periyasamy L. Bixin triggers apoptosis of human

Hep3B hepatocellular carcinoma cells: An insight to molecular and in silico approach. Nutrition and Cancer. 2018;**70**:1-13. DOI: 10.1080/01635581.2018.1490445

[38] Rojo de la Vega M, Zhang DD, Wondrak GT. Topical bixin confers NRF2-dependent protection against photodamage and hair graying in mouse skin. Frontiers in Pharmacology. 2018;**9**:287. DOI: 10.3389/fphar.2018.00287

[39] Tao S, Park SL, Rojo de la Vega M, Zhang DD, Wondrak GT. Systemic administration of the apocarotenoid bixin protects skin against solar UV-induced damage through activation of NRF2. Free Radical Biology and Medicine. 2015;**89**:690-700. DOI: 10.1016/j.freeradbiomed.2015.08.028

[40] Rojo de la Vega M, Krajisnik A, Zhang D, Wondrak G, Rojo de la Vega M, Krajisnik A, et al. Targeting NRF2 for improved skin barrier function and photoprotection: Focus on the achiote-derived apocarotenoid bixin. Nutrients. 2017;**9**:1371. DOI: 10.3390/nu9121371

[41] Ubillas R, Jolad SD, Bruening RC, Kernan MR, King SR, Sesin DF, et al. SP-303, an antiviral oligomeric proanthocyanidin from the latex of *Croton lechleri* (Sangre de Drago). Phytomedicine. 1994;**1**:77-106. DOI: 10.1016/S0944-7113(11)80026-7

[42] Gabriel SE, Davenport SE, Steagall RJ, Vimal V, Carlson T, Rozhon EJ. A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion. American Journal of Physiology. 1999;**276**:G58-G63

[43] Cottreau J, Tucker A, Crutchley R, Garey KW. Crofelemer for the treatment of secretory diarrhea. Expert Review of Gastroenterology & Hepatology. 2012;**6**:17-23. DOI: 10.1586/egh.11.87

- [44] Yeo QM, Crutchley R, Cottreau J, Tucker A, Garey KW. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. *Drugs Today*. 2013;**49**:239-252. DOI: 10.1358/dot.2013.49.4.1947253
- [45] Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from *Croton lechleri*, targets two distinct intestinal chloride channels. *Molecular Pharmacology*. 2010;**77**:69-78. DOI: 10.1124/mol.109.061051
- [46] Simić A, Soković MD, Ristić M, Grujić-Jovanović S, Vukojević J, Marin PD. The chemical composition of some *Lauraceae* essential oils and their antifungal activities. *Phytotherapy Research*. 2004;**18**:713-717. DOI: 10.1002/ptr.1516
- [47] dos Santos ÉRQ, Maia CSF, Fontes Junior EA, Melo AS, Pinheiro BG, Maia JGS. Linalool-rich essential oils from the Amazon display antidepressant-type effect in rodents. *Journal of Ethnopharmacology*. 2018;**212**:43-49. DOI: 10.1016/j.jep.2017.10.013
- [48] Branch LC, da Silva MF. Folk medicine of Alter do Chao, Pará. *Acta Amazonica*. 1983;**13**:737-797. DOI: 10.1590/1809-4392135737
- [49] Huo M, Cui X, Xue J, Chi G, Gao R, Deng X, et al. Anti-inflammatory effects of linalool in RAW 264.7 macrophages and lipopolysaccharide-induced lung injury model. *Journal of Surgical Research*. 2013;**180**: e47-e54. DOI: 10.1016/j.jss.2012.10.050
- [50] Rodenak-Kladniew B, Castro A, Stärkel P, De Saeger C, García de Bravo M, Crespo R. Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways. *Life Sciences*. 2018;**199**:48-59. DOI: 10.1016/j.lfs.2018.03.006
- [51] Gu Y, Ting Z, Qiu X, Zhang X, Gan X, Fang Y, et al. Linalool preferentially induces robust apoptosis of a variety of leukemia cells via upregulating p53 and cyclin-dependent kinase inhibitors. *Toxicology*. 2010;**268**:19-24. DOI: 10.1016/j.tox.2009.11.013
- [52] Shen Y-L, Wang T-Y, Chen T-Y, Chang M-Y. The proliferative inhibitor and apoptosis mechanism of linalool in breast cancer cells. *Biomarkers and Genomic Medicine*. 2013;**5**:131. DOI: 10.1016/j.bgm.2013.08.016
- [53] Pereira I, Severino P, Santos AC, Silva AM, Souto EB. Linalool bioactive properties and potential applicability in drug delivery systems. *Colloids and Surfaces B: Biointerfaces*. 2018;**171**:566-578. DOI: 10.1016/j.colsurfb.2018.08.001
- [54] Kohn LK, Queiroga CL, Martini MC, Barata LE, Porto PSS, Souza L, et al. In vitro antiviral activity of Brazilian plants (*Maytenus ilicifolia* and *Aniba rosaeodora*) against bovine herpesvirus type 5 and avian metapneumovirus. *Pharmaceutical Biology*. 2012;**50**:1269-1275. DOI: 10.3109/13880209.2012.673627
- [55] Jabir MS, Taha AA, Sahib UI. Linalool loaded on glutathione modified gold nanoparticles: A drug delivery system for a successful antimicrobial therapy. *Artificial Cells, Nanomedicine, and Biotechnology*. 2018;**46**:1-11. DOI:10.1080/21691401.2018.1457535
- [56] Ferreira GLS, Bezerra LMD, Ribeiro ILA, Morais Júnior RCD, Castro RD. Susceptibility of cariogenic microorganisms to phytoconstituents. *Brazilian Journal of Biology*. 2018;**78**:691-696. DOI: 10.1590/1519-6984.174147

- [57] Sarrazin SLF, Oliveira RB, Maia JGS, Mourão RHV. Antibacterial activity of the rosewood (*Aniba rosaeodora* and *A. parviflora*) linalool-rich oils from the Amazon. *European Journal of Medicinal Plants*. 2015;**12**:1-9
- [58] Pimentel RBQ, Souza DP, Albuquerque PM, Fernandes AV, Santos AS, Duvoisin S, et al. Variability and antifungal activity of volatile compounds from *Aniba rosaeodora* Ducke, harvested from Central Amazonia in two different seasons. *Industrial Crops and Products*. 2018;**123**:1-9. DOI: 10.1016/j.indcrop.2018.06.055
- [59] de Oliveira Lima MI, Araújo de Medeiros AC, Souza Silva KV, Cardoso GN, de Oliveira Lima E, de Oliveira Pereira F. Investigation of the antifungal potential of linalool against clinical isolates of fluconazole resistant *Trichophyton rubrum*. *Journal de Mycologie Médicale*. 2017;**27**:195-202. DOI: 10.1016/j.mycmed.2017.01.011
- [60] VM V, Dubey VK, Ponnuraj K. Identification of two natural compound inhibitors of *Leishmania donovani* spermidine synthase (SpdS) through molecular docking and dynamic studies. *Journal of Biomolecular Structure and Dynamics*. 2018;**36**:2678-2693. DOI: 10.1080/07391102.2017.1366947
- [61] Dutra FL, Oliveira MM, Santos RS, Silva WS, Alviano DS, Vieira DP, et al. Effects of linalool and eugenol on the survival of *Leishmania* (L.) infantum chagasi within macrophages. *Acta Tropica*. 2016;**164**:69-76. DOI: 10.1016/j.actatropica.2016.08.026
- [62] García Prado E, García Gimenez MD, De la Puerta Vázquez R, Espartero Sánchez JL, Sáenz Rodríguez MT. Antiproliferative effects of mitraphylline, a pentacyclic oxindole alkaloid of *Uncaria tomentosa* on human glioma and neuroblastoma cell lines. *Phytomedicine*. 2007;**14**:280-284. DOI: 10.1016/j.phymed.2006.12.023
- [63] Reis SRIN, Valente LMM, Sampaio AL, Siani AC, Gandini M, Azeredo EL, et al. Immunomodulating and antiviral activities of *Uncaria tomentosa* on human monocytes infected with dengue virus-2. *International Immunopharmacology*. 2008;**8**:468-476. DOI: 10.1016/j.intimp.2007.11.010
- [64] Sandoval-Chacón M, Thompson JH, Zhang XJ, Liu X, Mannick EE, Sadowska-Krowicka H, et al. Antiinflammatory actions of cat's claw: The role of NF-kappaB. *Alimentary Pharmacology & Therapeutics*. 1998;**12**:1279-1289
- [65] Allen-Hall L, Arnason JT, Cano P, Lafrenie RM. *Uncaria tomentosa* acts as a potent TNF-alpha inhibitor through NF-kappaB. *Journal of Ethnopharmacology*. 2010;**127**:685-693. DOI: 10.1016/j.jep.2009.12.004
- [66] Rojas-Duran R, González-Aspajo G, Ruiz-Martel C, Bourdy G, Doroteo-Ortega VH, Alban-Castillo J, et al. Anti-inflammatory activity of mitraphylline isolated from *Uncaria tomentosa* bark. *Journal of Ethnopharmacology*. 2012;**143**:801-804. DOI: 10.1016/j.jep.2012.07.015
- [67] Montserrat-de la Paz S, de la Puerta R, Fernandez-Arche A, Quilez AM, Muriana FJG, Garcia-Gimenez MD, et al. Pharmacological effects of mitraphylline from *Uncaria tomentosa* in primary human monocytes: Skew toward M2 macrophages. *Journal of Ethnopharmacology*. 2015;**170**:128-135. DOI: 10.1016/j.jep.2015.05.002
- [68] Fujita A, Sarkar D, Wu S, Kennelly E, Shetty K, Genovese MI. Evaluation of phenolic-linked bioactives of camucamu (*Myrciaria dubia* mc. Vaugh) for antihyperglycemia, antihypertension,

antimicrobial properties and cellular rejuvenation. Food Research International. 2015;77:194-203. DOI: 10.1016/j.foodres.2015.07.009

[69] Tauchen J, Bortl L, Huml L, Miksatkova P, Daskocil I, Marsik P, et al. Phenolic composition, antioxidant and anti-proliferative activities of edible and medicinal plants from the Peruvian Amazon. Revista Brasileira de Farmacognosia. 2016;26:728-737. DOI: 10.1016/j.bjp.2016.03.016

[70] dos Santos AE, Kuster RM, Yamamoto KA, Salles TS, Campos R, de Meneses MD, et al. Quercetin and quercetin 3-O-glycosides from *Bauhinia longifolia* (bong.) Steud. show anti-Mayaro virus activity. Parasites & Vectors. 2014;7:130. DOI: 10.1186/1756-3305-7-130

[71] D'Andrea G. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia. 2015;106:256-271. DOI: 10.1016/j.fitote.2015.09.018

[72] Wang W, Sun C, Mao L, Ma P, Liu F, Yang J, et al. The biological activities, chemical stability, metabolism and delivery systems of quercetin: A review. Trends in Food Science & Technology. 2016;56:21-38. DOI: 10.1016/j.tifs.2016.07.004

[73] Dajas F. Life or death: Neuroprotective and anticancer effects of quercetin. Journal of Ethnopharmacology. 2012;143:383-396. DOI: 10.1016/j.jep.2012.07.005

[74] Lesjak M, Beara I, Simin N, Pintać D, Majkić T, Bekvalac K, et al. Antioxidant and anti-inflammatory activities of quercetin and its derivatives. Journal of Functional Foods. 2018;40:68-75. DOI: 10.1016/j.jff.2017.10.047

[75] Suganthi N, Devi KP, Nabavi SF, Braidy N, Nabavi SM. Bioactive

effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. Biomedicine & Pharmacotherapy. 2016;84:892-908. DOI: 10.1016/j.biopha.2016.10.011

[76] Patel RV, Mistry BM, Shinde SK, Syed R, Singh V, Shin H-S. Therapeutic potential of quercetin as a cardiovascular agent. European Journal of Medicinal Chemistry. 2018;155:889-904. DOI: 10.1016/j.ejmech.2018.06.053

[77] Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemical Journal. 2000;351:95-105. DOI: 10.1042/bj3510095

[78] Cao H, Paufl JM, Hille R. X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin. Journal of Natural Products. 2014;77:1693-1699. DOI: 10.1021/np500320g

[79] Zhang C, Wang R, Zhang G, Gong D. Mechanistic insights into the inhibition of quercetin on xanthine oxidase. International Journal of Biological Macromolecules. 2018;112:405-412. DOI: 10.1016/j.ijbiomac.2018.01.190

[80] Hamilton KE, Rekman JF, Gunnink LK, Busscher BM, Scott JL, Tidball AM, et al. Quercetin inhibits glucose transport by binding to an exofacial site on GLUT1. Biochimie. 2018;151:107-114. DOI: 10.1016/j.biochi.2018.05.012

[81] Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 1997;385:602-609. DOI: 10.1038/385602a0

[82] Ugochukwu E, Soundararajan M, Rellos P, Fedorov O, Phillips C, Wang J, et al. Crystal Structure of Human Serine/Threonine Kinase 17B (STK17B) in Complex with Quercetin. RCSB PDB Protein Data Bank. 2010. DOI: 10.2210/pdb3lm5/pdb

- [83] Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. *Molecular Cell*. 2000;**6**:909-919
- [84] Vaisberg AJ, Milla M, Planas MC, Cordova JL, de Agusti ER, Ferreyra R, et al. Taspine is the cicatrizant principle in Sangre de Grado extracted from *Croton lechleri*. *Planta Medica*. 1989;**55**:140-143. DOI: 10.1055/s-2006-961907
- [85] Porras-Reyes BH, Lewis WH, Roman J, Simchowitz L, Mustoe TA. Enhancement of wound healing by the alkaloid taspine defining mechanism of action. *Proceedings of the Society for Experimental Biology and Medicine*. 1993;**203**:18-25
- [86] Fayad W, Fryknäs M, Brnjic S, Olofsson MH, Larsson R, Linder S. Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. *PLoS One*. 2009;**4**:e7238. DOI: 10.1371/journal.pone.0007238
- [87] Zhan Y, Zhang Y, Chen Y, Wang N, Zheng L, He L. Activity of taspine isolated from radix et *Rhizoma Leonticis* against estrogen-receptor-positive breast cancer. *Fitoterapia*. 2011;**82**:896-902. DOI: 10.1016/j.fitote.2011.05.004
- [88] Castelli S, Katkar P, Vassallo O, Falconi M, Linder S, Desideri A. A natural anticancer agent thaspine targets human topoisomerase IB. *Anti-Cancer Agents in Medicinal Chemistry*. 2013;**13**:356-363
- [89] Jako C, Coutu C, Roewer I, Reed DW, Pelcher LE, Covello PS. Probing carotenoid biosynthesis in developing seed coats of *Bixa orellana* (Bixaceae) through expressed sequence tag analysis. *Plant Science*. 2002;**163**:141-145. DOI: 10.1016/S0168-9452(02)00083-3
- [90] Cárdenas-Conejo Y, Carballo-Uicab V, Lieberman M, Aguilar-Espinosa M, Comai L, Rivera-Madrid R. De novo transcriptome sequencing in *Bixa orellana* to identify genes involved in methylerythritol phosphate, carotenoid and bixin biosynthesis. *BMC Genomics*. 2015;**16**:877. DOI: 10.1186/s12864-015-2065-4
- [91] Bouvier F, Dogbo O, Camara B. Biosynthesis of the food and cosmetic plant pigment bixin (annatto). *Science*. 2003;**300**:2089-2091. DOI: 10.1126/science.1085162
- [92] Dubey VS, Bhalla R, Luthra R. An overview of the non-mevalonate pathway for terpenoid biosynthesis in plants. *Journal of Biosciences*. 2003;**28**:637. DOI: 10.1007/BF02703339
- [93] Rohmer M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. *Natural Product Reports*. 1999;**16**:565-574
- [94] Zhu B-Q, Cai J, Wang Z-Q, Xu X-Q, Duan C-Q, Pan Q-H, et al. Identification of a plastid-localized bifunctional nerolidol/linalool synthase in relation to linalool biosynthesis in young grape berries. *International Journal of Molecular Sciences*. 2014;**15**:21992-22010. DOI: 10.3390/ijms151221992
- [95] Lichtenthaler HK, Schwender J, Disch A, Rohmer M. Biosynthesis of isoprenoids in higher plant chloroplasts proceeds via a mevalonate-independent pathway. *FEBS Letters*. 1997;**400**:271-274. DOI: 10.1016/S0014-5793(96)01404-4
- [96] Suga T, Shishibori T, Bukeo M. Biosynthesis of linalool in higher plants. *Phytochemistry*. 1971;**10**:2725-2726. DOI: 10.1016/S0031-9422(00)97272-8

[97] Chen C, Zheng Y, Zhong Y, Wu Y, Li Z, Xu L-A, et al. Transcriptome analysis and identification of genes related to terpenoid biosynthesis in *Cinnamomum camphora*. BMC Genomics. 2018;**19**:550. DOI: 10.1186/s12864-018-4941-1

[98] Okada K, Kasahara H, Yamaguchi S, Kawaide H, Kamiya Y, Nojiri H, et al. Genetic evidence for the role of isopentenyl diphosphate isomerases in the mevalonate pathway and plant development in *Arabidopsis*. Plant and Cell Physiology. 2008;**49**:604-616. DOI: 10.1093/pcp/pcn032

[99] Neti SS, Pan J-J, Poulter CD. Mechanistic studies of the protonation-deprotonation reactions for type 1 and type 2 isopentenyl diphosphate:dimethylallyl diphosphate isomerase. Journal of the American Chemical Society. 2018;**140**:12900-12908. DOI: 10.1021/jacs.8b07274

[100] Falcone Ferreyra ML, Rius SP, Casati P. Flavonoids: Biosynthesis, biological functions, and biotechnological applications. Frontiers in Plant Science. 2012;**3**:222. DOI: 10.3389/fpls.2012.00222

[101] Cheynier V, Comte G, Davies KM, Lattanzio V, Martens S. Plant phenolics: Recent advances on their biosynthesis, genetics, and ecophysiology. Plant Physiology and Biochemistry. 2013;**72**: 1-20. DOI: 10.1016/j.plaphy.2013.05.009